The MDR1-MDCK data are consistent with a lack of transport by the P-gp multidrug resistance protein and with passive diffusion across cellular membrane barriers, making RGN3067 a promising molecule for the treatment of brain and other CNS cancers protected by the BBB. This evidence concerns the gene PGP and central nervous system cancer.